Skip to main content
Celltrion Pharm Inc. logo

Celltrion Pharm Inc. — Investor Relations & Filings

Ticker · 068760 ISIN · KR7068760008 KO Manufacturing
Open in API
Filings indexed 336 across all filing types
Latest filing 2024-08-14 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 068760

About Celltrion Pharm Inc.

https://www.celltrionph.com/en-us/home/…

Celltrion Pharm Inc. is a pharmaceutical company specializing in the manufacturing and supply of chemical pharmaceuticals and biosimilar products. The company's portfolio includes treatments for various conditions, with a notable focus on biosimilars for autoimmune diseases. A key product is Remsima, a biosimilar of Infliximab, indicated for treating rheumatoid arthritis, Crohn's disease, ulcerative colitis, and psoriasis. As an integral part of the global biopharmaceutical company Celltrion, Celltrion Pharm distributes its products to both domestic and international markets, contributing to the accessibility of advanced biologic therapies.

Recent filings

Filing Released Lang Actions
반기보고서 (2024.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for Celltrion Pharm, Inc. for the period ending June 30, 2024. It contains detailed financial information, business operations, capital structure, and management discussions, which are characteristic of an interim financial report. It is not a mere announcement or certification, but the full report itself. H1 2024
2024-08-14 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This type of filing is a standard regulatory requirement for directors and major shareholders to disclose changes in their shareholdings, which falls under the 'Director's Dealing' category (DIRS).
2024-07-12 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This type of filing is a standard regulatory requirement for major shareholders (in this case, Celltrion reporting on its stake in Celltrion Pharm) to disclose changes in their shareholdings. In the context of the provided categories, this falls under 'Major Shareholding Notification' (MRQ) as it details the change in ownership percentage and the specific number of shares held by a major shareholder.
2024-05-31 Korean
대규모기업집단현황공시[연1회공시및1/4분기용(개별회사)]
Major Shareholding Notification Classification · 100% confidence The document is a 'Status Disclosure of Large Business Groups' (기업집단현황공시) filed by Celltrion Pharm. This is a mandatory regulatory filing in South Korea that provides detailed information on corporate structure, financial status, board composition, shareholding, and internal transactions. Since it does not fit into specific categories like 10-K (Annual Report) or ER (Earnings Release), and is a formal regulatory disclosure required by the Korea Fair Trade Commission, it is classified as a Regulatory Filing (RNS).
2024-05-31 Korean
분기보고서 (2024.03)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for Celltrion Pharm, covering the period from January 1, 2024, to March 31, 2024. It contains detailed financial data, business operations, product information, and research and development activities, which are characteristic of an interim financial report. It is not a mere announcement or certification, but the full report itself. Q1 2024
2024-05-16 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Service in South Korea. It details the share ownership changes of an executive (Woo Young-je) at Celltrion Pharm. This type of filing is a standard regulatory disclosure for insider transactions or changes in holdings by company directors/executives, which corresponds to the 'Director's Dealing' category.
2024-05-03 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.